Daniel Wang

9.9k total citations · 2 hit papers
58 papers, 2.2k citations indexed

About

Daniel Wang is a scholar working on Oncology, Immunology and Molecular Biology. According to data from OpenAlex, Daniel Wang has authored 58 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 20 papers in Immunology and 11 papers in Molecular Biology. Recurrent topics in Daniel Wang's work include Cancer Immunotherapy and Biomarkers (21 papers), Immunotherapy and Immune Responses (11 papers) and CAR-T cell therapy research (10 papers). Daniel Wang is often cited by papers focused on Cancer Immunotherapy and Biomarkers (21 papers), Immunotherapy and Immune Responses (11 papers) and CAR-T cell therapy research (10 papers). Daniel Wang collaborates with scholars based in United States, Australia and Canada. Daniel Wang's co-authors include Douglas B. Johnson, Yukiko Kiniwa, Kui Shin Voo, Tihui Fu, Guangyong Peng, Zhong Guo, Helen Y. Wang, Rongfu Wang, Yanchun Li and Weiyi Peng and has published in prestigious journals such as Science, Blood and The Journal of Immunology.

In The Last Decade

Daniel Wang

53 papers receiving 2.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Toll-Like Receptor 8-Mediated Reversal of CD4 ⁺ Regulatory T Cell Function

2005 603 citations Guangyong Peng, Zhong Guo et al. Science profile →
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

2014 409 citations Daniel Wang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Daniel Wang United States	21	811	800	564	461	197	58	2.2k
Tadakazu Kondo Japan	31	734 0.9×	1.1k 1.3×	1.0k 1.8×	433 0.9×	133 0.7×	196	3.3k
Ollivier Hyrien United States	23	325 0.4×	266 0.3×	428 0.8×	351 0.8×	159 0.8×	79	1.7k
Janice M. Mehnert United States	25	363 0.4×	1.5k 1.9×	1.0k 1.8×	941 2.0×	438 2.2×	89	2.7k
Sabina Berezowska Switzerland	27	622 0.8×	538 0.7×	926 1.6×	427 0.9×	590 3.0×	114	2.4k
Fan Xia China	24	233 0.3×	540 0.7×	614 1.1×	266 0.6×	281 1.4×	115	1.9k
Kun Jiang United States	29	698 0.9×	771 1.0×	1.0k 1.8×	199 0.4×	222 1.1×	83	2.4k
Yong Cai China	24	296 0.4×	910 1.1×	944 1.7×	221 0.5×	203 1.0×	103	2.3k
Xiaojin Wu China	21	687 0.8×	480 0.6×	841 1.5×	153 0.3×	108 0.5×	124	2.0k
Gregory Riedlinger United States	22	453 0.6×	749 0.9×	728 1.3×	154 0.3×	321 1.6×	54	1.9k

Countries citing papers authored by Daniel Wang

Since Specialization

Citations

This map shows the geographic impact of Daniel Wang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Daniel Wang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Daniel Wang more than expected).

Fields of papers citing papers by Daniel Wang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Daniel Wang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Daniel Wang. The network helps show where Daniel Wang may publish in the future.

Co-authorship network of co-authors of Daniel Wang

This figure shows the co-authorship network connecting the top 25 collaborators of Daniel Wang. A scholar is included among the top collaborators of Daniel Wang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Daniel Wang. Daniel Wang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chen, Natalie, Daniel Wang, Caroline E. Porter, et al.. (2023). Abstract P3-06-04: Treatment of Metastatic Breast Cancer with Multipotent Oncolytic/Helper Adenovirus CAdVEC. Cancer Research. 83(5_Supplement). P3–6. 2 indexed citations

Villabona-Rueda, A.F., Daniel Wang, & Franco R. D’Alessio. (2023). Experimental Model to Evaluate Resolution of Pneumonia. Journal of Visualized Experiments. 1 indexed citations

Ito, Satoko, et al.. (2023). Setting Cost-Effective Price Thresholds before FDA Approval: Cost-Effectiveness of Iptacopan Monotherapy Versus Standard-of-Care Anti-C5 Therapy in Transfusion-Dependent, Treatment-Experienced Adult Patients with Paroxysmal Nocturnal Hemoglobinuria in the United States. Blood. 142(Supplement 1). 5042–5042. 1 indexed citations

Wang, Daniel, et al.. (2023). Effect of chimeric antigen receptor T cells against protease-activated receptor 1 for treating pancreatic cancer. BMC Medicine. 21(1). 338–338. 7 indexed citations

Florez, Marcus A., Anita L. Sabichi, Daniel Wang, et al.. (2022). Persistent Ethnicity-Associated Disparity in Antitumor Effectiveness of Immune Checkpoint Inhibitors Despite Equal Access. Cancer Research Communications. 2(8). 806–813. 20 indexed citations

Tchakarov, Amanda, et al.. (2022). The Use of Rituximab in Treatment of Immune Checkpoint Inhibitor Induced Glomerulonephritis. Journal of the American Society of Nephrology. 33(11S). 374–374.

Jang, Hee-Jin, Hyun‐Sung Lee, Wendong Yu, et al.. (2022). Therapeutic Targeting of Macrophage Plasticity Remodels the Tumor-Immune Microenvironment. Cancer Research. 82(14). 2593–2609. 9 indexed citations

Lee, Hyun‐Sung, Hee-Jin Jang, Maheshwari Ramineni, et al.. (2022). A Phase II Window of Opportunity Study of Neoadjuvant PD-L1 versus PD-L1 plus CTLA-4 Blockade for Patients with Malignant Pleural Mesothelioma. Clinical Cancer Research. 29(3). 548–559. 25 indexed citations

Dearden, Helen Clare, Lewis Au, Daniel Wang, et al.. (2021). Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy. European Journal of Cancer. 153. 168–178. 24 indexed citations

10.

Johnson, Douglas B., Justine V. Cohen, Alexandra M. Haugh, et al.. (2019). Anti–PD-1–Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma Patients. Cancer Immunology Research. 7(11). 1755–1759. 20 indexed citations

11.

McKinney, K. A., Daniel Wang, Jianhuai Ye, et al.. (2019). A sampler for atmospheric volatile organic compounds by copter unmanned aerial vehicles. Atmospheric measurement techniques. 12(6). 3123–3135. 53 indexed citations

12.

Saab, Karim R., Meghan J. Mooradian, Daniel Wang, et al.. (2018). Tolerance and efficacy of BRAF plus MEK inhibition in patients with melanoma who previously have received programmed cell death protein 1‐based therapy. Cancer. 125(6). 884–891. 40 indexed citations

13.

Wang, Daniel, Zeynep Eroglu, Alpaslan Özgün, et al.. (2017). Clinical Features of Acquired Resistance to Anti–PD-1 Therapy in Advanced Melanoma. Cancer Immunology Research. 5(5). 357–362. 35 indexed citations

14.

Wang, Daniel, et al.. (2017). Successful Treatment of Alemtuzumab Induced Immune Thrombocytopenia with a Thrombopoietin Receptor Agonist. Blood. 130. 2326–2326.

15.

Wang, Daniel & Kaitlin M. Bratlie. (2015). Influence of Polymer Chemistry on Cytokine Secretion from Polarized Macrophages. ACS Biomaterials Science & Engineering. 1(3). 166–174. 21 indexed citations

16.

Subrath, Joan, Daniel Wang, Biqi Wu, et al.. (2009). C-5 Substituted heteroaryl 3-pyridinecarbonitriles as PKCθ inhibitors: Part I. Bioorganic & Medicinal Chemistry Letters. 19(18). 5423–5425. 16 indexed citations

17.

Ho, Melisa W-Y., Bijia Deng, Stephen C. Benoit, et al.. (2009). Comparison of Dexamethasone and Cyclosporine to selective protein Kinase C-theta inhibitor effects on blood IL-2 production and T cell activation (35.32). The Journal of Immunology. 182(Supplement_1). 35.32–35.32. 3 indexed citations

18.

Chaudhary, Divya, Diane H. Boschelli, Andrea G. Bree, et al.. (2009). Characterization of a selective Protein Kinase C theta (PKCθ) inhibitor for blocking T Cell responses (93.21). The Journal of Immunology. 182(Supplement_1). 93.21–93.21. 1 indexed citations

19.

Dimitrakakis, Constantine, Jian Zhou, Jie Wang, et al.. (2006). Co-expression of estrogen receptor-alpha and targets of estrogen receptor action in proliferating monkey mammary epithelial cells. Breast Cancer Research. 8(1). R10–R10. 10 indexed citations

20.

Peng, Guangyong, Zhong Guo, Yukiko Kiniwa, et al.. (2005). Toll-Like Receptor 8-Mediated Reversal of CD4 ⁺ Regulatory T Cell Function. Science. 309(5739). 1380–1384. 603 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact